Back

Dapagliflozin reduces loop diuretic requirement over time in patients with heart failure with mildly reduced or preserved ejection fraction in the DELIVER Trial

20 May 2023 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Safia Chatur

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

6 More presentations in this session

Presentation thumbnail
Real-world use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish heart failure registry
Doctor D. Stolfo (Udine, IT)
Abstract Slides Video
Presentation thumbnail
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial.
Doctor J. Tromp (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Safety of continuing mineralocorticoid receptor antagonists treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from swedish heart failure registry
Doctor F. Guidetti (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure
Ms I. Beldhuis (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Impact of lower systolic blood pressure on efficacy and safety of sacubitri/valsartan compared to ramipril in patients with acute myocardial infarction: insights from PARADISE-MI trial
Doctor M. Senni (Bergamo, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy
Video

The Event

Event poster

Heart Failure 2023

20 May - 23 May 2023
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?
thumbnail
Congress Session
Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources